Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-P53
- Development stage
- Phase 3
- Lead developer
- Celltrion
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CT-P53 is a proposed biosimilar of ocrelizumab, a humanized monoclonal antibody targeting CD20. It is being developed by Celltrion as a treatment for multiple sclerosis, specifically relapsing-remitting multiple sclerosis (RRMS). The drug is designed to match the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety profile of the reference product Ocrevus. Ocrelizumab works by selectively depleting CD20-positive B cells implicated in the pathogenesis of multiple sclerosis[1][2][6][8].
- Other names
- ocrelizumab biosimilarCelltrion ocrelizumab biosimilar
02
Targets
Beyond the preview
Go deeper on CT-P53.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-P53.